跳至主要内容
临床试验/NCT02249169
NCT02249169已完成不适用

Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2014年9月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
84
试验地点
1
主要终点
Change in gut microbiome in patients with IBS compared to healthy individuals measured over 6 months

研究概览

简要总结

This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of IBS-C or IBS-D
  • Age 18 to 65

排除标准

  • Prior history of abdominal surgeries (except appendectomy and cholecystectomy)
  • Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory condition
  • Antibiotic use within the past 4 weeks (they can be enrolled after a four-week washout period and subsequent use during the 6-month study duration does not exclude them)
  • Bleeding risk or medications which may increase risk of bleeding for patients who agree to undergo flexible sigmoidoscopy
  • Bowel preparation for colonoscopy within the past week
  • Pregnancy or plans to become pregnant within the study time frame
  • Vulnerable adults
  • Age greater than or equal to 66
  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of the study, would increase risks of flexible sigmoidoscopy (for those opting for this), or in the judgment of the investigator would potentially interfere compliance to this study or would adversely affect study outcomes
  • HEALTHY SUBJECTS:
  • Inclusion Criteria:
  • Age 18 to 65
  • No clinical diagnosis of IBS-C or IBS-D
  • Exclusion Criteria:
  • Prior history of abdominal surgeries (except appendectomy and cholecystectomy)
  • Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory condition
  • Antibiotic use within the past 4 weeks (they can be enrolled after a four-week washout period and subsequent use during the 6-month study duration does not exclude them)
  • Bleeding risk or medications which may increase risk of bleeding for patients who agree to undergo flexible sigmoidoscopy
  • Bowel preparation for colonoscopy within the past week
  • Pregnancy or plans to become pregnant within the study time frame
  • Vulnerable adults
  • Age greater than or equal to 66
  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of the study, would increase risks of flexible sigmoidoscopy (for those opting for this), or in the judgment of the investigator would potentially interfere compliance to this study or would adversely affect study outcomes
  • Clinical diagnosis of IBS-C or IBS-D

结局指标

主要结局

Change in gut microbiome in patients with IBS compared to healthy individuals measured over 6 months

时间窗: baseline, 6 months

Participants will provide a stool sample at baseline and at periodic intervals for 6 months to assess gut microbial composition.

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Purna C. Kashyap, MBBS

PI

Mayo Clinic

研究点 (1)

Loading locations...

相似试验

Developing Novel Microbiota-Targeted Therapies for... | 临床试验